Probiotics and refractory chronic spontaneous urticaria
E Nettis1, E Di Leo2, A Pastore3
1Department of Allergy and Clinical Immunology, University of Bari Policlinico, Piazza Giulio Cesare 11, 70124 Bari, Italy. Phone: +39 080 5592 821 Fax: +39 080 5593 576
European Annals of Allergy and Clinical Immunology
|September 9, 2016
Summary
A combination of two probiotics, Lactobacillus salivarius LS01 and Bifidobacterium breve BR03, showed potential benefits for some patients with chronic spontaneous urticaria (CSU) refractory to antihistamines. The treatment may improve urticaria symptoms and quality of life in a subset of patients.
Area of Science:
- Immunology
- Microbiology
- Dermatology
Background:
- Chronic spontaneous urticaria (CSU) often requires advanced therapies when antihistamines are insufficient.
- Refractory CSU necessitates exploration of novel and safe treatment options.
Purpose of the Study:
- To assess the efficacy and safety of a probiotic combination (Lactobacillus salivarius LS01 and Bifidobacterium breve BR03) in CSU patients with persistent symptoms despite H1-antihistamine treatment.
- To evaluate the impact of probiotic supplementation on urticaria activity and quality of life.
Main Methods:
- A study involving 52 patients with refractory CSU treated with a daily mixture of Lactobacillus LS01 and Bifidobacterium BR03 for 8 weeks.
- Clinical progress was monitored using the Urticaria Activity Score over 7 days (UAS7) and a quality of life questionnaire.
- The study was conducted across two Italian specialist urticaria clinics between September 2013 and September 2014.
Main Results:
- Out of 38 evaluable patients, 23.7% experienced mild improvement, 2.6% significant improvement, and 2.6% complete remission of urticaria.
- 71.1% of patients did not report symptom improvement.
- No adverse side effects were reported during the probiotic treatment period.
Conclusions:
- The probiotic combination of Lactobacillus salivarius LS01 and Bifidobacterium breve BR03 may offer symptomatic relief and improve quality of life for some CSU patients unresponsive to H1 antihistamines.
- Potential benefits were more noted in patients with co-existing allergic rhinitis.
- Further research may be warranted to identify patient subgroups who benefit most from this probiotic intervention.
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
2.2K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.2K
01:21Drugs for Treatment of Constipation-Predominant IBS
1.1K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.1K
01:28Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
1.1K
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
1.1K
01:19Antiasthma Drugs: Leukotriene Modifiers
2.1K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
2.1K
01:17Chronic Bowel Disorders: Introduction
874
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
874
01:17Drugs for Treatment of Diarrhea-Predominant IBS
836
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
836